Plan for problems before treatment
Include later contact in the care comparison. Ask for a plan tied to the drug being discussed, beyond the broad word peptide.
- Ask whom to contact with a concern.
- Have unclear product instructions clarified by the care team.
- Know the distinction between follow-up and urgent help.
Get the product-specific answers
For injectable products, FDA’s letters to peptide sellers stress possible serious harm from bypassing the body’s barriers to toxins and germs.
That is a reason to ask precise questions about the product, rather than looking for a general reassurance about peptides. Ask the prescriber what problems matter for the medicine being considered and what would change the plan.
Compounding means mixing or changing medicine for an individual need.
Germs can get into a drug when compounding is done poorly; the amount of the working ingredient can be wrong too, FDA says.
A drug’s action comes from its active ingredient. Ask who can answer questions about the preparation and who handles questions about your health. Keep those contact routes together, without assuming they lead to the same person.
Ask before relying on unclear instructions
Two names in these checks are semaglutide and tirzepatide. The September 2026 approval record includes medicines made with these ingredients for diabetes and weight management. They sit in the group often called GLP-1 medicines; these medicines imitate a hormone called GLP-1. The hormone is involved in appetite as well as blood sugar.
Unclear directions
FDA recorded reports of mistakes with compounded semaglutide in the September 2026 review; some people needed hospital care.
If the written instructions and the explanation you heard seem different, bring the mismatch to the pharmacist or prescriber. Ask for an explanation tied to the actual product in hand.
Storage and delivery
Storage differs by drug: reviewed labels include approved peptide products kept at room temperature and ones kept cold.
Ask how the proposed medicine is meant to travel, where it belongs when it arrives and whom to contact about a delivery concern. A rule copied from a different medicine is not the same as the instructions for yours.
FDA says not to use an injectable GLP-1 drug after a warm delivery or inadequate cooling, which can affect the drug’s quality.
Plan for the questions that come later
Ask how a new symptom or a change in your health reaches the prescriber. Ask what happens outside the usual reply window and where to seek an assessment if the remote service cannot provide one. Have the plan written in language you can use.
Reactions at the place of injection differ by product; there is no shared rate across all peptide injections.
Bring up pregnancy, plans for pregnancy and breastfeeding in the care conversation. Ask the clinician who is assessing your health to discuss the exact medicine being considered. Keep that discussion specific instead of relying on a rule for an entire group of drugs.
The reviewed labels give different pregnancy advice for semaglutide and tirzepatide; the wording for one does not stand in for the other.
Ask what information you can take home and how it relates to any custom preparation. If an answer is missing, keep it as an open question for the person making the decision.
Know when the situation is urgent
MedlinePlus calls a severe allergic reaction anaphylaxis; it can threaten life and come on in seconds or minutes.
MedlinePlus says severe allergic signs call for 911 or the local emergency service: these include breathing trouble, difficulty swallowing and a swollen face or tongue.
This is an urgent-help note, rather than a way to diagnose yourself. Keep the ordinary message route and the emergency route distinct when discussing the follow-up plan.
FDA’s MedWatch program accepts suspected drug-problem reports from the public; such a report, by itself, does not establish a drug as the cause.